BACKGROUND:Warfarin is a commonly used anticoagulant in North America. Several generic formulations have been approved, raising concern over the safety and efficacy of these products compared with brand-name Coumadin. OBJECTIVE: To ensure that generic warfarin products can be safely interchanged with Coumadin. METHODS: Multiple n-of-1 randomized, double-blind, crossover trials switched outpatients (N = 7) between a generic warfarin formulation (Apo-warfarin) and Coumadin over 30 weeks. Study patients took each drug for five 3-week periods, with international normalized ratio (INR) measurements taken twice per period. Inter- and intrapatient differences between generic warfarin and Coumadin were compared, and overall study patient results were compared with those of a Coumadin control group. RESULTS: There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required. There also was no difference in INR variation based on warfarin formulation (p > 0.69), nor was a patient and warfarin interaction found (p > 0.81). The INR results were not influenced by whether patients were maintained on Coumadin only (control group) or interchanged between Coumadin and generic warfarin (p = 0.98). CONCLUSIONS: It appears that patients can safely and effectively switch between generic warfarin and Coumadin.
RCT Entities:
BACKGROUND:Warfarin is a commonly used anticoagulant in North America. Several generic formulations have been approved, raising concern over the safety and efficacy of these products compared with brand-name Coumadin. OBJECTIVE: To ensure that generic warfarin products can be safely interchanged with Coumadin. METHODS: Multiple n-of-1 randomized, double-blind, crossover trials switched outpatients (N = 7) between a generic warfarin formulation (Apo-warfarin) and Coumadin over 30 weeks. Study patients took each drug for five 3-week periods, with international normalized ratio (INR) measurements taken twice per period. Inter- and intrapatient differences between generic warfarin and Coumadin were compared, and overall study patient results were compared with those of a Coumadin control group. RESULTS: There were no differences between warfarin products in terms of mean INR results or number of dosage adjustments required. There also was no difference in INR variation based on warfarin formulation (p > 0.69), nor was a patient and warfarin interaction found (p > 0.81). The INR results were not influenced by whether patients were maintained on Coumadin only (control group) or interchanged between Coumadin and generic warfarin (p = 0.98). CONCLUSIONS: It appears that patients can safely and effectively switch between generic warfarin and Coumadin.
Authors: Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork Journal: Per Med Date: 2011-03 Impact factor: 2.512
Authors: Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank Journal: JAMA Date: 2008-12-03 Impact factor: 56.272
Authors: Lamberto Manzoli; Maria Elena Flacco; Stefania Boccia; Elvira D'Andrea; Nikola Panic; Carolina Marzuillo; Roberta Siliquini; Walter Ricciardi; Paolo Villari; John P A Ioannidis Journal: Eur J Epidemiol Date: 2015-11-30 Impact factor: 8.082
Authors: Gowri Raman; Ethan M Balk; Lana Lai; Jennifer Shi; Jeffrey Chan; Jennifer S Lutz; Robert W Dubois; Richard L Kravitz; David M Kent Journal: BMJ Open Date: 2018-05-26 Impact factor: 2.692
Authors: Martin H Prins; Alexia Marrel; Paulo Carita; David Anderson; Marie-Germaine Bousser; Harry Crijns; Silla Consoli; Benoit Arnould Journal: Health Qual Life Outcomes Date: 2009-02-06 Impact factor: 3.186
Authors: Chalachew Alemayehu; Geoffrey Mitchell; Abraham Aseffa; Alexandra Clavarino; James McGree; Jane Nikles Journal: Trials Date: 2017-10-10 Impact factor: 2.279